STOP THE SHOTS (AND THE SPRAYS): Sprayable COVID Vaccine Trial Raises ‘Significant Safety Concerns’. Several scientists and researchers questioned the design of the trial for the CVXGA1 nasal vaccine, suggesting the trial did not examine “if shed materials can be spread to others.” The trial also included just 72 participants and lacked an unvaccinated control group. By Michael Nevradakis, Ph.D. (07/09/25; includes links and related articles)

childrenshealthdefense.…

ED NOTE
Many people choose NOT to get vaccinated with COVID shots or anything else. If the research described below becomes reality and sprayable vaccines become widespread (pun fully intended), none of us will have a choice. Just as none of us have a choice about material being sprayed into our skies to control the weather. 

We already don't have much choice about avoiding second-hand vaccination, as shedding can happen with current vaccines, including RSV and COVID shots. But sprayable (and self replicating) vaccines are far more likely to spread from person to person, so unless you choose to live in a bubble, you might be unable to escape them.

If HHS agencies (FDA, CDC, etc.) approve this hideous entry from Big Harma's arsenal, we'll have no choice but to conclude the agencies remain fully captured, even under a new administration.

Summary (Grok ai, edited; image from article)

A Phase 1 clinical trial for CVXGA1, a sprayable intranasal mRNA COVID-19 vaccine by CyanVac LLC, reported effectiveness and minimal adverse reactions in a study published in Science Advances.

However, safety alarm bells are ringing loudly due to: Trial's small sample size, lack of an unvaccinated control group, and potential risks of viral shedding.

Because the vaccine uses a communicable parainfluenza virus type 5 vector to produce the SARS-CoV-2 spike protein, it may pose health risks due to persistent shedding and immune system impacts.

The trial, funded by CyanVac (the manufacturer), had serious design flaws and researcher affiliations with pharmaceutical companies, including Pfizer.

Trial Details and Findings

• Study Overview: Phase 1 trial of CVXGA1, an intranasal mRNA vaccine, was published in Science Advances.

• Participants: 72 individuals, ages 12-53, split into high-dose and low-dose groups.

• Results:

  • High-dose group showed lower rates of symptomatic COVID-19.

  • Vaccine reported as well-tolerated with no serious adverse events or fever.

• Next Steps: Researchers plan to enroll 10,000 participants for the next trial phase.

Egregiously Flawed Trial Design

• No Control Group: No unvaccinated control group, undermining safety and efficacy claims.

• Small Sample Size: Limited to 72 participants, weakening data reliability.

• Open-Label Design: Participants and researchers knew who received the high and low-dose vaccine, risking bias.

• Limited Adverse Event Tracking: Monitored only during a short time frame, potentially missing long-term issues.

• Missing Data: No data on RNA detection levels, infectivity assays, or adolescent-specific safety.

Safety and Shedding Concerns

• Viral Shedding Risk:

  • CVXGA1 uses parainfluenza virus type 5, a communicable respiratory virus.

  • Potential to shed viral particles through nasal secretions, risking exposure to unvaccinated individuals.

  • A 2023 RSV vaccine study showed 17% of participants shed virus.

• Spike Protein Risks:

  • Vaccine produces SARS-CoV-2 spike protein, linked to potential health risks in prior mRNA vaccines.

  • Experts warn of immune system antagonism from spike protein.

• Expert Opinions:

  • Sonia Elijah: Shedding risks unstudied, raising public safety concerns.

  • Karl Jablonowski, Ph.D.: Self-spreading vaccine may infect vulnerable populations without consent.

  • Karina Acevedo Whitehouse, Ph.D.: High likelihood of persistent shedding based on similar vaccines.

Funding and Conflicts of Interest

• Trial Funding: Fully funded by CyanVac LLC.

• Researcher Affiliations:

  • Some researchers are CyanVac employees, equity holders, or under contract.

  • Others received grants from AstraZeneca, Moderna, and Pfizer.

• Trial Site History:

  • Conducted at Cincinnati Children’s Hospital, led by Dr. Paul Spearman.

  • Hospital previously hosted Pfizer’s adolescent COVID-19 vaccine trials.

  • Case of Maddie de Garay: 12-year-old injured post-Pfizer vaccine, injuries dismissed as unrelated.

Related:

• Shedding of Covid mRNA Vaccine Components and Products From the Vaccinated to the Unvaccinated.By PIERRE KORY, MD, MPA. Part 1 includes links to the entire nine-part series: tinyurl.com/3nph9thm

• OpenVAERS (COVID adverse events, underreported): tinyurl.com/yc76t5xe

• React19 (vaccine injured, includes many scientific studies shown COVID-19 shot harms): tinyurl.com/5mhm8xsy

• Maddie de Garay’s story (search results on React19):